HC Wainwright Reaffirms “Buy” Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $221.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 26.42% from the company’s previous close.

Several other research firms have also issued reports on KRYS. Chardan Capital lifted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Citigroup boosted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $215.83.

Krystal Biotech Trading Down 0.9 %

Krystal Biotech stock opened at $174.82 on Friday. The firm has a market capitalization of $5.04 billion, a price-to-earnings ratio of 58.52 and a beta of 0.84. The firm has a 50 day simple moving average of $159.13 and a 200 day simple moving average of $175.30. Krystal Biotech has a 1-year low of $141.72 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period in the prior year, the firm posted $0.30 earnings per share. The company’s revenue for the quarter was up 116.4% on a year-over-year basis. On average, equities research analysts forecast that Krystal Biotech will post 6.14 EPS for the current year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 14.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of KRYS. Wilmington Savings Fund Society FSB bought a new stake in Krystal Biotech in the third quarter valued at approximately $40,000. Huntington National Bank raised its holdings in Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after buying an additional 283 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Krystal Biotech during the 4th quarter valued at $95,000. KBC Group NV grew its holdings in Krystal Biotech by 25.9% in the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after acquiring an additional 132 shares during the last quarter. Finally, Covestor Ltd increased its position in shares of Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after acquiring an additional 642 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).